Načítá se...
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes degradation of the LDLR [LDL (low-density lipoprotein) receptor] through an as-yet-undefined mechanism, leading to a reduction in cellular LDLc (LDL-cholesterol) and a concomitant increase in serum LDLc. Central to the function of PCSK9...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Portland Press Ltd.
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2669217/ https://ncbi.nlm.nih.gov/pubmed/19196236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20082407 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|